Equities
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)279.18
  • Today's Change2.13 / 0.77%
  • Shares traded485.38k
  • 1 Year change-7.92%
  • Beta0.4659
Data delayed at least 20 minutes, as of May 10 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Jun 30 2023202320222021
ASSETS
Cash And Short Term Investments1,55710,4411,814
Total Receivables, Net1,9361,5131,648
Total Inventory5,4664,3333,781
Prepaid expenses300174148
Other current assets, total------
Total current assets9,25916,4617,390
Property, plant & equipment, net9,3528,3097,536
Goodwill, net8,0791,1871,188
Intangibles, net8,3671,4511,482
Long term investments17340322
Note receivable - long term96136.60
Other long term assets------
Total assets36,23428,34618,157
LIABILITIES
Accounts payable820592523
Accrued expenses2,3731,8811,728
Notes payable/short-term debt3910279
Current portion long-term debt/capital leases1,0164,392395
Other current liabilities, total360141378
Total current liabilities4,6087,1083,104
Total long term debt11,1725,1645,333
Total debt12,2279,6585,807
Deferred income tax1,464670459
Minority interest2,040----
Other liabilities, total1,164826880
Total liabilities20,44813,7699,776
SHAREHOLDERS EQUITY
Common stock5174,988--
Additional paid-in capital------
Retained earnings (accumulated deficit)15,24714,04012,679
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total22(4451)(4298)
Total equity15,78614,5788,381
Total liabilities & shareholders' equity36,23428,34618,157
Total common shares outstanding482482455
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.